<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A significant proportion of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients are resistant to anti-ERBB1 [avian erythroblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> (v-erb-b) oncogene homolog, receptor for EGF] monoclonal antibodies (Mabs) </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated both immune and nonimmune effects of cetuximab (anti-ERBB1 Mab), trastuzumab (anti-ERBB2 Mab), pertuzumab (anti-ERBB2 Mab), and <z:chebi fb="0" ids="49603">lapatinib</z:chebi> (dual ERBB1 and ERBB2 <z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi>) in a large well-characterized panel of 64 CRC cell lines to find response predictive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> characteristics </plain></SENT>
<SENT sid="2" pm="."><plain>There was a significant correlation between the direct effects of cetuximab and <z:chebi fb="0" ids="49603">lapatinib</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Both agents were associated (P = 0.0004) with "triple' <z:mp ids='MP_0002169'>wild-type</z:mp> status in KRAS, BRAF, and PIK3CA exon 20 </plain></SENT>
<SENT sid="4" pm="."><plain>Most cell lines were resistant to the direct effects of anti-ERBB2 Mabs, suggesting that the effects of <z:chebi fb="0" ids="49603">lapatinib</z:chebi> might mainly be through ERBB1 </plain></SENT>
<SENT sid="5" pm="."><plain>Microarray <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression profiles of sensitive and resistant cell lines showed that although ERBB1 receptor or ligand levels did not associate with cetuximab sensitivity, high levels of ERBB2 (P = 0.036) and amphiregulin (P = 0.026) predicted sensitivity to <z:chebi fb="0" ids="49603">lapatinib</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>However, higher ERBB1 expression predicted susceptibility to cetuximab-induced antibody-dependent cellular cytotoxicity and occurred independently of KRAS/BRAF/PIK3CA mutations (P = 0.69) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="49603">Lapatinib</z:chebi> may be an effective alternative therapy to cetuximab in triple <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Microarray analysis provides suggestive biomarkers for resistance </plain></SENT>
<SENT sid="9" pm="."><plain>ERBB1 levels, independent of mutation status, predict immune killing </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, anti-ERBB1 antibodies may be considered in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with higher ERBB1 expression and favorable FcÎ³R polymorphisms </plain></SENT>
</text></document>